374 related articles for article (PubMed ID: 16271909)
1. RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Am J Med; 2005 Nov; 118(11):1250-5. PubMed ID: 16271909
[TBL] [Abstract][Full Text] [Related]
2. RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.
Ishida Y; Kawai S
Am J Med; 2004 Oct; 117(8):549-55. PubMed ID: 15465502
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine as a predictive factor for hip fracture in older persons.
McLean RR; Jacques PF; Selhub J; Tucker KL; Samelson EJ; Broe KE; Hannan MT; Cupples LA; Kiel DP
N Engl J Med; 2004 May; 350(20):2042-9. PubMed ID: 15141042
[TBL] [Abstract][Full Text] [Related]
4. RETRACTED: An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients.
Sato Y; Iwamoto J; Honda Y
J Stroke Cerebrovasc Dis; 2011; 20(1):41-46. PubMed ID: 20598577
[TBL] [Abstract][Full Text] [Related]
5. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
6. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
7. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
Yasui K; Nakaso K; Kowa H; Takeshima T; Nakashima K
Acta Neurol Scand; 2003 Jul; 108(1):66-7. PubMed ID: 12807397
[No Abstract] [Full Text] [Related]
9. RETRACTED: I do not even remember what I smoked! A case of marijuana-induced transient global amnesia.
Mansour G; Abuzaid A; Bellamkonda P
Am J Med; 2014 Nov; 127(11):e5-e6. PubMed ID: 25019359
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia?
Zoccolella S; Lamberti SV; Iliceto G; Santamato A; Lamberti P; Logroscino G
Curr Med Chem; 2010; 17(28):3253-61. PubMed ID: 20666719
[TBL] [Abstract][Full Text] [Related]
12. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
[TBL] [Abstract][Full Text] [Related]
13. Retracted: Effects of Vitamin K2 on Osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Pharm Des; 2004; 10(21):2557-76. PubMed ID: 15320745
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Vertebral, Hip, and Femoral Fractures Among Patients With Parkinson's Disease: A 5-Year Follow-up in Korea.
Park SB; Chung CK; Lee JY; Lee JY; Kim J
J Am Med Dir Assoc; 2019 May; 20(5):617-623. PubMed ID: 30366761
[TBL] [Abstract][Full Text] [Related]
15. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
17. Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
Müller T; Muhlack S
Parkinsonism Relat Disord; 2010 Dec; 16(10):688-9. PubMed ID: 20719554
[No Abstract] [Full Text] [Related]
18. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Di Rocco A; Werner P
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14981202
[No Abstract] [Full Text] [Related]
19. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
[TBL] [Abstract][Full Text] [Related]
20. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Schroecksnadel K; Leblhuber F; Fuchs D
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14994447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
